Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07227922 · ClinicalTrials.gov registry record · Phase 1
Clofutriben Pharmacokinetics in Patients With Impaired Renal Function
A Phase 1 study of Moderate Renal Impairment, sponsored by Sparrow Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT07227922: Recruiting Phase 1 study of Moderate Renal Impairment, sponsored by Sparrow Pharmaceuticals.
NCT07227922 is a Phase 1 study of Moderate Renal Impairment that is actively recruiting participants, run by Sparrow Pharmaceuticals. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07227922, a Phase 1 study of Moderate Renal Impairment, is actively recruiting participants, sponsored by Sparrow Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1, single-center, open-label, single-dose trial. Sixteen participants are planned: 8 participants with moderate renal impairment and 8 matched control participants with normal renal function.
Primary Outcome
Conclusions that clofutriben and AS2570469 exposures (separately) are not altered by moderate renal impairment will be reached if the 95% CIs of the geometric mean estimates of AUC0-t, AUC0-inf, and Cmax of clofutriben and AS2570469 fall within the \[60%, 140%\] range.
Conditions Studied
Interventions
- DRUG 12mg clofutriben
Study Locations (1)
Florida
- Orlando Clinical Research Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-11-30 |
| Est. Completion | 2026-07-01 |
| Phase | Phase 1 |
What NCT07227922 shows while recruiting
NCT07227922 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Moderate Renal Impairment appearing as the primary indexed condition, and to 1 intervention - of which 12mg clofutriben is the first listed.
NCT07227922 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07227922 about?
NCT07227922 is a clinical study titled "Clofutriben Pharmacokinetics in Patients With Impaired Renal Function". This is a Phase 1, single-center, open-label, single-dose trial. Sixteen participants are planned: 8 participants with moderate renal impairment and 8 matched control participants with normal renal function.
What is the current status of trial NCT07227922?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-11-30. Estimated completion is 2026-07-01.
What conditions does trial NCT07227922 study?
This clinical trial studies the following conditions: Moderate Renal Impairment.
What interventions are being tested in trial NCT07227922?
The interventions under investigation include: 12mg clofutriben (DRUG).
Who is sponsoring clinical trial NCT07227922?
This trial is sponsored by Sparrow Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07227922 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07227922's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI